LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
=== February === 9 February – The Scottish Prison Service concludes its review of accommodating transgender prisoners, and recommends that transgender prisoners initially be accommodated according to their sex at birth while an individual assessment is carried out. 10 February – Following a legal challenge by lap dance performers and club owners, a ban on lap dancing clubs in Edinburgh, scheduled to come into force in April, is overturned by Edinburgh's Court of Session after it finds Edinburgh City Council acted illegally by voting to limit the number of sexual entertainment venues in the city from four to zero. 15 February – Nicola Sturgeon announces her resignation as First Minister of Scotland and Leader of the Scottish National Party after eight years in the role; she will stay on until her successor has been elected. 16 February – Deputy First Minister John Swinney rules himself out of the SNP leadership contest. 17 February – The Royal College of Nursing recommends its members accept a new pay offer of 6.5%. The offer from the Scottish Government also includes changes to conditions. 19 February Scottish Health Secretary Humza Yousaf and former Minister for Community Safety Ash Regan become the first two candidates to announce they will stand in the Scottish National Party leadership election. Keith Brown, the SNP's depute leader, Neil Gray, the Minister for International Development, and Màiri McAllan, the Environment Minister, all rule themselves out of the contest.
Compound characterization with TLC is also possible and is similar to reaction monitoring. However, rather than spotting with starting material and reaction mixture, it is with an unknown and a known compound. They may be the same compound if both spots have the same RF and look the same under the chosen visualization method. However, co-elution complicates both reaction monitoring and characterization. This is because different compounds will move to the same spot on the plate. In such cases, different solvent mixtures may provide better separation.
== Work == In 1934 Flory joined the Central Department of Dupont and Company working with Wallace H. Carothers. After Carothers' death in 1937, Flory worked for two years at the Basic Research Laboratory located in the University of Cincinnati. During World War II, there was a need for research to develop synthetic rubber, so Flory joined the Esso Laboratories of the Standard Oil Development Company. From 1943 to 1948 Flory worked in the polymer research team of the Goodyear Tire and Rubber Company. In 1948, Flory gave the George Fisher Baker lectures at Cornell University, and subsequently joined the university as a professor. In 1957, Flory and his family moved to Pittsburgh, Pennsylvania, where Flory was executive director of research at the Mellon Institute of Industrial Research. In 1961, he took up a professorship at Stanford University in the department of chemistry. After retirement, Flory remained active in the world of chemistry, running research labs both in Stanford, and IBM.
Ion-exchange chromatography separates molecules based on their respective charged groups. Ion-exchange chromatography retains analyte molecules on the column based on coulombic (ionic) interactions. The ion exchange chromatography matrix consists of positively and negatively charged ions. Essentially, molecules undergo electrostatic interactions with opposite charges on the stationary phase matrix. The stationary phase consists of an immobile matrix that contains charged ionizable functional groups or ligands. The stationary phase surface displays ionic functional groups (R-X) that interact with analyte ions of opposite charge. To achieve electroneutrality, these immobilized charges couple with exchangeable counterions in the solution. Ionizable molecules that are to be purified, compete with these exchangeable counterions, for binding to the immobilized charges on the stationary phase. These ionizable molecules are retained or eluted based on their charge. Initially, molecules that do not bind or bind weakly to the stationary phase are first to be washed away. Altered conditions are needed for the elution of the molecules that bind to the stationary phase. The concentration of the exchangeable counterions, which competes with the molecules for binding, can be increased, or the pH can be changed to affect the ionic charge of the eluent or the solute. A change in pH affects the charge on the particular molecules and, therefore, alter their binding. When reducing the net charge of the solute's molecules, they start eluting out.
For example, people with migraine are more likely to become anxious and depressed, but people with anxiety and depression also have a higher risk of becoming affected by migraine. The most frequently reported migraine trigger for women is hormonal variation, followed by stress for both women and men. Disrupted sleep, fasting, missing meals, dehydration, and sensory overstimulation are also commonly reported triggers. There is strong evidence that hormonal changes, stress, quality of sleep, and fasting are causally related to migraine attacks. These "catalyst triggers" may increase activity in the hypothalamus or trigeminal system of the brain until it exceeds the brain's migraine threshold. From puberty onwards, women experience migraine attacks more frequently and with greater severity than men, particularly for migraine without aura. The incidence of attacks of migraine without aura is strongly related to hormonal fluctuations in estrogen, both monthly and across a woman's lifespan. Keeping the body's internal environment stable and consistent appears to protect the brain's migraine sensitivity threshold, while disruption and stresses may make it more likely for the brain to go past its sensitivity threshold. Lifestyle changes that support stability, such as regular sleep, regular meals, and stress management, can help to prevent migraines. Whether a possible trigger is an actual cause or an early symptom, it may be possible to reduce discomfort by managing exposure to sensory stimuli such as smells, lights, sound, or touch.
Sources: en.wikipedia.org
A medical laboratory or clinical laboratory is a laboratory where tests are done on biological specimens in order to get information about the health of a patient. Such laboratories may be divided into categorical departments such as microbiology, hematology, clinical biochemistry, immunology, serology, histology, cytology, cytogenetics, or virology. In many countries, there are two main types of labs that process the majority of medical specimens. Hospital laboratories are attached to a hospital, and perform tests on these patients. Private or community laboratories receive samples from general practitioners, insurance companies, and other health clinics for analysis. A biomedical research facility is where basic research or applied research is conducted to aid the body of knowledge in the field of medicine. Medical research can be divided into two general categories: the evaluation of new treatments for both safety and efficacy in what are termed clinical trials, and all other research that contributes to the development of new treatments. The latter is termed preclinical research if its goal is specifically to elaborate knowledge for the development of new therapeutic strategies.
=== Continuous-flow fast atom bombardment === CE can be coupled to fast atom bombardment ionization using a continuous flow interface. The interface must match the flow rate between the two systems. The CF-FAB requires a relatively high flow rate but CE need low flow rate for better separation. A make-up flow can be used using a sheath flow or liquid junction.
Vegetables can be eaten either raw or cooked and play an important role in human nutrition, being mostly low in fat and carbohydrates, but high in vitamins, minerals and dietary fiber. Many nutritionists encourage people to consume plenty of fruit and vegetables, five or more portions a day often being recommended.
=== Fourth wave (2016–present) === The fourth wave, which began in 2016, is characterized by polysubstance use and increased use of stimulants like methamphetamines and cocaine. Additionally, this wave is characterized by the emergence of novel adulterants, such as xylazine and more recently medetomidine in the fentanyl supply. The availability and use of illicit fentanyl continue to be the leading cause of fatalities, but the recent rise of polysubstance use, defined as the practice of using multiple drugs at once or in succession, and stimulants, is linked to the increased fatality rate with the ongoing opioid epidemic. Between 2012 and 2018, there was a threefold increase in mortality related to cocaine use, and a fivefold increase in mortality related to psychostimulants like methamphetamine. This increase has primarily been observed in male populations from non-Hispanic American Indian, non-Hispanic Black, and non-Hispanic White populations. Researchers attribute the increase in illicit drug use to the CDC's recommendations to reduce opioid use through measures like tapering opioid prescribing. In 2023, opioid deaths began a sustained decline after peaking at 73,000 that year. Deaths declined by over 1/3 in 2024. The decline is attributed to the reduced availability of fentanyl precursors from China, as the quality of fentanyl decline along supply chains affecting production in both Mexico and China.
In Gilbert syndrome, unless another disease of the liver is also present, the liver enzymes ALT/SGPT and AST/SGOT, as well as albumin, are within normal ranges. Crigler–Najjar syndrome (types I and II), a different glucuronyl transferase disorder, is much more severe, with 0–10% UGT1A1 activity, with affected individuals at risk of brain damage in infancy (type I) and teenage years (type II). Hemolysis of any cause can be excluded by a full blood count, haptoglobin, lactate dehydrogenase levels, and the absence of reticulocytosis (elevated reticulocytes in the blood would usually be observed in haemolytic anaemia). Dubin–Johnson syndrome and Rotor syndrome are rarer autosomal recessive disorders characterized by an increase of conjugated bilirubin. Viral hepatitis associated with increase of conjugated bilirubin can be excluded by negative blood samples for antigens specific to the different hepatitis viruses. Cholestasis can be excluded by normal levels of bile acids in plasma, the absence of lactate dehydrogenase, low levels of conjugated bilirubin, and ultrasound scan of the bile ducts. Vitamin B12 deficiency – elevated bilirubin levels (and MCV counts above 90–92) can be associated with a vitamin B12 deficiency.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.